Browse studies

Find your next paid study

3,234 recruiting studies matching your filters

An Early Phase 1 Trial to Assess Pharmacodynamic Effects of OMO-103 in Patients With Pancreatic Ductal Adenocarcinoma

This early phase I trial studies the biological activity of OMO-103 in patients with pancreatic ductal adenocarcinoma that has spread to nearby tissue or lymph…

Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8+2 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

OHSU Knight Cancer InstituteNCT07089940

Protoacoustic Imaging for 3D Mapping the Bragg Peak in Real Time During Proton Therapy (PROTEUS)

The purpose of this study is to test a new imaging technology called radioacoustic imaging (RAI) that may help doctors see where radiation is being delivered d…

Proton TherapyRadiation Therapy, Secondary Skin ReactionsLiver Cancer+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of OklahomaNCT07832617

Observational

Randomized Controlled Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the sta…

Bladder CancerMuscle-Invasive Bladder CarcinomaUrothelial Carcinoma+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Thomas Jefferson UniversityNCT07234968

Phase 1

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 AS MONOTHERAPY AND COMBINATION THERAPY IN ADULT PARTICIPANTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatmen…

Carcinoma, HepatocellularHepatocellular CancerHepatocellular Carcinoma+4 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

PfizerNCT07227012

Phase 2

Evaluation of Gixam's Performance in a FIT Negative Population

In the United States, colorectal cancer ranks second to lung cancer as a cause of cancer death and is the third most commonly occurring cancer in both men and …

Colorectal AdenomaColorectal Cancer (CRC)Colorectal Cancer (CRC) Screening

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Jubaan Ltd.NCT06612281

Phase 1

SENTINEL-101: A Phase 1 Dose Escalation and Expansion Study of CLSP-5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors That Harbor the KRas G12V Mutation

Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\…

Advanced Solid TumorNon Small Cell Lung CancerPancreatic Carcinoma+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Clasp Therapeutics, Inc.NCT07650357

Phase 2

A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)

This phase II trial tests how well elacestrant with everolimus works for the treatment of estrogen receptor (ER) positive endometrial cancer that has come back…

Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaRecurrent Endometrial Carcinoma+2 more

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Jonsson Comprehensive Cancer CenterNCT07634601

Phase 2

A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy a…

HER2-negativeGastroesophageal JunctionEsophageal Adenocarcinoma+1 more

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Gilead SciencesNCT07546812

Phase 1

Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)

This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus \[CMV\] specific cytotoxic …

Allogeneic Hematopoietic Stem Cell Transplantation RecipientCytomegalovirusDonor+2 more

Estimated

~$500 – $11,250

Actual pay is set by the research site.

Sumithira VasuNCT03665675

Phase 1

Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's Lymphoma

This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen rec…

B-Cell Non-Hodgkin Lymphoma-RecurrentDiffuse Large B-Cell Lymphoma-RecurrentFollicular Lymphoma-Recurrent+9 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Phase 1

Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma

In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PAC…

Advanced Solid Tumor Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Immunolight, LLCNCT04389281

Phase 1

An Open Label, Phase 1b Safety, Dose-finding, Brain Tumor Delivery, and Pharmacokinetics Study of Intranasal NEO100 in Patients With Pediatric-type Select Brain Tumors

This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type dif…

Pediatric Tumor of CNSPediatric Tumor of BrainDiffuse Midline Glioma, H3 K27M-Mutant+5 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Neonc Technologies, Inc.NCT06357377